The study compares two different approaches to giving albumin solution to transplant patients. In one group, patients receive albumin to maintain higher blood levels (above 30 grams per liter), while the other group receives albumin only when their levels fall very low (20 grams per liter or below). The treatment continues for five days after the transplant surgery.

Throughout the study, doctors monitor various aspects of patient recovery, including kidney function, infections, time spent in the intensive care unit, and how well the transplanted liver is working. They also track other important factors such as the need for breathing support and the body’s immune response to the transplant.

The main purpose of this study is to determine if Treg02 treatment is safe and well-tolerated in liver transplant patients who are taking tacrolimus alone, and whether it can help patients eventually stop taking their anti-rejection medication. During the study, patients will receive paracetamol and dimetindene as supportive medications. The treatment involves taking blood from the patient, processing it to isolate and multiply specific immune cells in a laboratory, and then giving these cells back to the patient through an injection into a vein.

The study will monitor patients for any side effects from the treatment, particularly focusing on reactions to the cell infusion, infections, and signs of organ rejection. Patients will undergo regular check-ups, including blood tests and tissue samples from the transplanted liver, to ensure their safety and evaluate how well the treatment is working. The total duration of patient monitoring in the study will be approximately 14 months after receiving the cell treatment.

Participants in the study will be given different formulations of Mycophenolate Mofetil, including both generic and brand-name versions, to see if there are any differences in how the body absorbs them when taken with Pantoprazole. The study will compare these formulations to determine if they are bio-equivalent, meaning they work in the same way and provide the same benefits. The study will last for a short period, with participants taking the medications orally, which means by mouth.

The trial aims to provide valuable information on how these medications interact, which could help improve treatment for transplant patients. By understanding the influence of Pantoprazole on Mycophenolate Mofetil, healthcare providers can make better-informed decisions about medication management in post-transplant care. The study is expected to conclude by the end of 2025.

The purpose of the study is to evaluate how safe this combination of medications is for patients who have had a liver transplant and are dealing with a return of liver cancer. The study will observe patients over a period of six months to see how their bodies respond to the treatment. During this time, the patients will also receive a standard treatment to help prevent their bodies from rejecting the transplanted liver. The study aims to ensure that the treatment does not cause any harmful effects on the liver or the overall health of the patients.

Throughout the study, patients will be monitored regularly to check for any side effects or changes in their condition. This will include regular imaging tests, like CT scans, to track the progress of the cancer and assess the overall health of the patients. The study will also look at how long patients live without the cancer getting worse and how the treatment affects their quality of life. The goal is to gather information that can help improve treatment options for patients with advanced liver cancer who have had a liver transplant.

The trial will compare two different forms of the drug tacrolimus, which are Envarsus and Advagraf, to see if they are equally effective in preventing treatment failure. Treatment failure is defined as any of the following events: patient death, loss of the transplanted liver, or acute rejection of the liver, which is confirmed by a biopsy. The study will also compare the effects of taking CellCept once a day versus twice a day.

Participants in the study will be monitored for up to 18 months after their liver transplant. The study will look at various outcomes, including the proportion of deaths, loss of the transplanted liver, and cases of acute rejection. It will also assess the quality of life and any side effects experienced by the participants. The goal is to determine the most effective and safe way to administer these immunosuppressive drugs to liver transplant recipients.

The purpose of the study is to see if using a low dose of argipressin during the liver transplant surgery can help reduce the risk of developing AKI afterward. Participants in the study will receive either the argipressin treatment or a placebo during their surgery. The study will monitor the participants for a period after the surgery to observe any effects on kidney function and other health outcomes.

Throughout the study, various health indicators will be tracked, such as the need for blood transfusions, the use of other medications like norepinephrine, and the overall health status of the participants. The study aims to provide valuable information on whether this treatment can improve outcomes for patients undergoing liver transplants and help prevent complications like AKI.

Participants in the study will receive the DSIMC treatment after their liver transplant. The study will monitor the safety of this treatment over a period of 12 months. Additionally, researchers will assess how many patients can be completely weaned off immunosuppressive medications by 36 months after their transplant, while still maintaining optimal liver function. For those who cannot be completely weaned off, the level of immunosuppression they require will also be evaluated.

This trial is designed to help improve the outcomes for liver transplant patients by potentially reducing the long-term need for immunosuppressive drugs, which can have significant side effects. The study is expected to start recruiting participants in August 2024 and aims to conclude by September 2030.

Participants in the study will be patients undergoing organ transplants. The study will involve the use of either Custodiol-N or Custodiol during the organ preservation process. The trial will monitor the function of the transplanted organs and any potential injuries that may occur after the transplantation. The study will also track various health indicators over a period of time to assess the success of the organ transplants.

The trial is designed to be prospective, meaning it will follow patients over time to observe outcomes. It is also randomized, which means participants will be randomly assigned to receive either Custodiol-N or Custodiol. The study is single-blind, so the patients will not know which solution they are receiving, but the researchers will. This approach helps ensure that the results are unbiased and reliable. The study is expected to continue until the end of 2025.

The purpose of this study is to see how well these solutions work in preserving the liver during transplantation. Participants in the study will receive either Custodiol-N or Custodiol. The study will monitor the health of the liver after transplantation by measuring certain markers in the blood over a period of seven days. These markers include GPT (a liver enzyme), LDH (an enzyme that can indicate tissue damage), and other factors like bilirubin and INR (a measure of blood clotting).

Throughout the study, researchers will also look at other aspects of liver function and health, such as the occurrence of cholestasis (a condition where bile cannot flow from the liver to the duodenum), therapy for cholangitis (inflammation of the bile duct system), and any episodes of biliary leakage or strictures. The study aims to provide valuable information on which solution might be more effective in supporting liver health during and after transplantation.

Participants in the study will be taking either Envarsus or Prograf for a period of up to 12 months. During this time, their cognitive function, which includes attention and memory, will be assessed through various tests. These tests are designed to measure how well participants can focus, remember, and process information. Additionally, the study will look at the overall quality of life of the participants, which includes their physical and mental well-being.

The trial will also monitor any side effects or changes in liver and kidney function that may occur during the study. This information will help determine the safety and effectiveness of the once-daily Tacrolimus formulation compared to the twice-daily version. The study aims to provide valuable insights into how these medications can impact cognitive function and quality of life in liver transplant patients.